Kekkan Biologics
PrivateLast Round
Grant
Jul 5, 2023
Total Funding Raised
$670,000
Company Overview
Kekkan Biologics is a biotechnology company that develops first-in-class bispecific antibodies targeting lymphatic and vascular angiogenesis to treat metastatic cancers and fibrotic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kekkan Biologics Comparables
Compare Kekkan Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Massalia Therapeutics | 73% | |
| SPIMA Therapeutics | 70% | |
| PharmAbcine Inc. | 66% | |
Kekkan Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 5, 2023 |
Kekkan Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Landmark BioVentures AG | Accelerator |
| Bpifrance | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 5, 2023
$670K grant received from Bpifrance.
Kekkan Biologics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Kekkan Biologics's valuation, stock price, and market status.